Overall, according to the increased expression of Nrf2 in leukemia cells, it can be concluded that mere or combined inhibition of Nrf2 signaling pathways with other immuno/chemotherapeutic agents such as RTX and CP can be a new and potential therapeutic strategy and our newly designed NPs can be an optimal way of drug delivery with these purposes. Here, CP is linked to leukemia.